Skip to main content

Leishmaniasis, Cutaneous

3
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
3 programs
1
1
1
Arnica TincturePhase 31 trial
Experimental topicalPhase 1/21 trial
Arnica TincturePhase 11 trial
Active Trials
NCT05094908Active Not Recruiting16Est. Aug 2025
NCT04072874Withdrawn0Est. Jul 2022
NCT06822478Recruiting96Est. Feb 2030
Combined Therapeutics
1 program
meglumine antimoniate, allopurinolN/A1 trial
Active Trials
NCT00480883Completed400Est. Dec 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Innovation PharmaceuticalsArnica Tincture
Innovation PharmaceuticalsExperimental topical
Innovation PharmaceuticalsArnica Tincture
Combined Therapeuticsmeglumine antimoniate, allopurinol

Clinical Trials (4)

Total enrollment: 512 patients across 4 trials

NCT06822478Innovation PharmaceuticalsArnica Tincture

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

Start: Mar 2026Est. completion: Feb 203096 patients
Phase 3Recruiting
NCT04072874Innovation PharmaceuticalsExperimental topical

Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.

Start: Jan 2021Est. completion: Jul 20220
Phase 1/2Withdrawn
NCT05094908Innovation PharmaceuticalsArnica Tincture

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis

Start: May 2023Est. completion: Aug 202516 patients
Phase 1Active Not Recruiting
NCT00480883Combined Therapeuticsmeglumine antimoniate, allopurinol

Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol

Start: Jan 2008Est. completion: Dec 2008400 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 512 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.